Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

234.56
+4.061.76%
Post-market: 234.560.00000.00%18:18 EDT
Volume:601.35K
Turnover:140.34M
Market Cap:30.37B
PE:-107.64
High:235.12
Open:230.48
Low:228.96
Close:230.50
Loading ...
Apr 29, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 29, 2021

Major Issues Report

8-K - Current report
Apr 12, 2021

Major Issues Report

8-K - Current report
Feb 11, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 11, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 11, 2021

Major Issues Report

8-K - Current report
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 03, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 01, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 29, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 14, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 11, 2021

Major Issues Report

8-K - Current report
Nov 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 05, 2020

Major Issues Report

8-K - Current report
Oct 02, 2020

Major Issues Report

8-K - Current report
Aug 20, 2020

Major Issues Report

8-K - Current report
Aug 06, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 06, 2020

Major Issues Report

8-K - Current report
May 11, 2020

Major Issues Report

Current report, items 5.07 and 9.01